Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Upsher-Smith inks deal with Lundbeck
November 2013
SHARING OPTIONS:

MAPLE GROVE, Minn.—Pharmaceutical company Upsher-Smith Laboratories Inc., which focuses primarily on the development of therapies for the treatment of central nervous system diseases, has announced the establishment of a preclinical development agreement between Proximagen Ltd., its U.K. subsidiary, and H. Lundbeck AS to advance its protein kinase inhibitors research program. The agreement is congruent with Upsher-Smith’s long-term strategy to advance its branded drugs product portfolio. No financial terms were released.
 
“Upsher-Smith is pleased to announce today’s development agreement with Lundbeck. We are very impressed with the world-class research conducted by Lundbeck and excited about the opportunity to bring a new therapy forward that may benefit patients,” Mark Evenstad, president and CEO of Upsher-Smith Laboratories, said in a press release about the deal.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.